Phase 1 HR+/HER2- Breast Cancer Clinical Trials
8 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–8 of 8 trials
Recruiting
Phase 1
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Advanced HR+/HER2- Breast Cancer
Novartis Pharmaceuticals194 enrolled2 locationsNCT07604571
Recruiting
Phase 1Phase 2
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled9 locationsNCT07288359
Recruiting
Phase 1
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Triple Negative Breast Cancer(TNBC)HR+ Breast CancerHR+/HER2- Breast Cancer+1 more
NiKang Therapeutics, Inc.361 enrolled14 locationsNCT07029399
Recruiting
Phase 1Phase 2
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
HR+/HER2- Advanced Breast CancerHR+/HER2- Breast Cancer
Avenzo Therapeutics, Inc.380 enrolled14 locationsNCT06998407
Recruiting
Phase 1Phase 2
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
HR+/HER2- Breast Cancer
Faeth Therapeutics32 enrolled3 locationsNCT07558733
Recruiting
Phase 1Phase 2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 1Phase 2
Study of AVZO-021 in Patients With Advanced Solid Tumors
Endometrial CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+6 more
Avenzo Therapeutics, Inc.430 enrolled13 locationsNCT05867251
Recruiting
Phase 1Phase 2
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Advanced Solid TumorHR+/HER2- Breast Cancer
Beta Pharma (Suzhou) Co., Ltd.224 enrolled1 locationNCT04282031